Asterias Biotherapeutics — Investor Presentation (August 2016)
36 slides from Asterias Biotherapeutics's investor presentation, Aug 22, 2016
Slide 1: Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology
Clinical-Stage Cell Therapy Programs Addressing Significant Unmet Medical Needs in Neurology and Oncology Asterias Biotherapeutics NYSE: ASTAugust 2016 14219863Text 04698Text 230237246Text
Slide 2: Forward-Looking Statements
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute
Slide 3: Strong Leadership Team with Proven Track Record
Strong Leadership Team with Proven Track Record Name Experience Steve CarttPresident and CEO Former COO of Questcor PharmaceuticalsLed Questcor’s 2007-2014 commercial strategy, turnaround and multiple expansionsGrew company revenue from $10 million to $1 billionOver 30 years of experience in pharma
Slide 4: Key Highlights
Key Highlights AST-OPC1 (Pluripotent stem cell platform)Ongoing Phase 1/2a trial in spinal cord injury (SCI)Positive safety profile to-date in two safety cohorts (thoracic SCI trial and cervical SCI trial) Early signs of possible efficacy - one motor level improvement in all three patients in very l
Slide 5: Development Pipeline
PROGRAM PRECLIN PHASE 1 PHASE 2 PHASE 3 STATUS AST-OPC1*Spinal Cord Injury (subacute) Ph 1/2a ongoing AST-VAC1**Leukemia (AML) Autologous Process development & enhancement in progress AST-VAC2**Lung Cancer Allogeneic Planning Ph 1/2a start Q1 2017 * Potential for application in advanced MS, stroke**
Slide 6: Clinical-Stage Regenerative Platform Technologies
Pluripotent Stem Cells Scalable source from well-established stem cell lines to produce desired cell types resulting in “off the shelf” therapeutics to restore functional tissueAST-OPC1: Neural cell type (oligodendrocyte progenitor cells, OPCs); multiple MOAs to restore lost function in neurodegener
Slide 7: AST-OPC1
Pluripotent stem cell platformSignificant grant funding from California Institute of Regenerative Medicine (CIRM)Phase 1/2a clinical trial in spinal cord injury in progress AST-OPC1 14219863Text 04698Text 230237246Text
Slide 8: Spinal Cord Injury: High Unmet Medical Need, Substantial Commercial Opportunity
Spinal Cord Injury: High Unmet Medical Need, Substantial Commercial Opportunity Spinal cord injury (SCI) affects 17,000 patients per year in U.S.(1)Primarily affects young/healthy males in their 20s and 30s at time of injuryCan be devastating to quality of life and ability to engage in activities of
Slide 9: AST-OPC1: >4,000 patients addressable with target initial SCI label
AST-OPC1: >4,000 patients addressable with target initial SCI label, plus 5,000 additional patients through SCI label expansion 17,000 new SCI cases in the US annually(1) >4,000 under first label C4-C7 ASIA A/B/C 2016 NSCIC SCI Facts and Figures at a GlanceEstimates by indication calculated based on
Slide 10: AST-OPC1 Addresses the Complex Pathology of SCI
AST-OPC1 is a cellular therapy utilizing oligodendrocyte progenitor cells (OPCs) AST-OPC1 is made from a well-established , pluripotent embryonic stem cell line originally created in the 1990s; can serve entire OPC1 product lifecycleImportantly, no fetal tissue or adult cells are usedOPCs, which fun
Slide 11: AST-OPC1 Supported by Extensive Pre-Clinical Evaluation
AST-OPC1 Supported by Extensive Pre-Clinical Evaluation 14219863Text 04698Text 230237246Text Activity Induces persistent myelinationSecretes neurotrophic factorsInduces vascularizationReduces parenchymal cavitation Biodistribution Migrates up 5cm in spinal cordNo distribution outside central nervous
Slide 12: AST-OPC1 Trial in Cervical SCI: FDA Recently Cleared for Expansion
AST-OPC1 Trial in Cervical SCI: FDA Recently Cleared for Expansion 14219863Text 04698Text 230237246Text 2016 2017 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 6m Efficacy DMC Cohort 2 – 10M5 subjects AIS-ACohorts AIS-BCohorts Cohort 3 – 20M5 subjects C2 -6m efficacy C2 - 12m efficacy 10M5-8 subjects 20M5-8 subjects Obta
Slide 13: AST-OPC1 Expansion & Acceleration Highlights
AST-OPC1 Expansion & Acceleration Highlights Addition of two cohorts of AIS-B patients (5-8 subjects each at 10M & 20M cells)On average they have more spared tissue than AIS-A patients, which may lead to greater OPC1-mediated tissue repair and neurological recoveryExpansion to up to 8 AIS-A patients
Slide 14: Initial Phase in Thoracic SCI: Well Tolerated, Signs of Clinical Activity on MRI
Initial Phase 1 in Thoracic SCI: Well Tolerated, Signs of Clinical Activity on MRI A Phase 1 Trial was conducted in five patients with neurologically complete, thoracic SCITrial was not expected to demonstrate efficacy – low dose of 2 million AST-OPC1 cells was administered (5-10x below predicted ef
Slide 15: Ongoing Phase 1/2a Study in Cervical SCI: Well Tolerated, Signs of Clinical Activity
Phase 1 of the Ongoing Phase 1/2a Study in Cervical SCI: Well Tolerated, Measurable Signs of Clinical Activity Phase 1 very low dose (2 million cells), safety-only portion of the ongoing trial was conducted in three patients with neurologically complete, cervical SCINo safety issues observed, confir
Slide 16: AST-OPC1 Therapy is Designed to Increase Patient Motor Function
AST-OPC1 Therapy is Designed to Increase Patient Motor Function and Improve Ability to Self-Care Capability C1-C3 C4 C5 C6 C7-C8 Bowel Bladder Bed Mobility Transfers Pressure Relief Eating Dressing Grooming Bathing Wheelchair Car Transport Daily Home Care 24 hr Attendant 18-24 hr Attendant 6-12 hr A
Slide 17: Projected AST-OPC1 Data Milestones
Milestone Est. Date 6 month data from AIS-A Cohort 2 (10M cells) January 2017 12 month data from AIS-A Cohort 2 (10M cells) July 2017 6 month data from AIS-B Cohort 1 (10M cells) Q3 2017 6 month data from AIS-A Cohort 3 (20M cells) Q4 2017 12 month data from AIS-B Cohort 1 (10M cells) Q1 2018 6 mont
Slide 18: AST-VAC1
Patient-specific (autologous)Acute Myelogenous Leukemia (AML)Process development/enhancement in progress AST-VAC1 14219863Text 04698Text 230237246Text
Slide 19: AST-VAC1 Targets AML Need in Older and High-Risk Patients
~19,000 new AML cases diagnosed and ~10,500 deaths from AML in U.S. annually(1)AML incidence increases markedly after 60, and older patients do not tolerate AML therapies wellAverage age of an AML patient is 67Patients over 60 often have trouble tolerating intensive treatmentMany are poor candidates
Slide 20: AST-VAC1: Activating a Patient's Immune System
AST-VAC1: Activating a Patient’s Immune System Dendritic Cells: Potent Antigen Presenting Cells AST-VAC1 is an autologous cell-based immunotherapy that enables a patient’s own dendritic cells (DCs) to stimulate an immune response to telomerase, a universal cancer antigenIsolated monocytes are stimul
Slide 21: VAC Technology is Designed to Overcome Limitations of First-Generation Dendritic Cell Therapies
VAC Technology is Designed to Overcome Limitations of First-Generation Dendritic Cell Therapies Six distinct design characteristics differentiate Asterias’ VAC products from first-generation DC therapies LAMP sequenceEnhance immune response to telomerase Cryopreserved productSimplify supply chain Ma
Slide 22: AST-VAC1 Has Potential to Safely Maintain AML Remission
AST-VAC1 Has Potential to Safely Maintain AML Remission AML Two-Step Treatment Paradigm: Induction and Maintenance of Remission Step 1: InductionChemotherapy to get patients into complete remissionMost new AML therapies in development are targeting Induction of Remission Step 2: Consolidation/Mainte
Slide 23: Proof of Concept in Phase 2 Trial
57% 10-20% >60 years oldN = 7 20-40% 58% All patientsN = 19 Relapse Free Survival at 52 Months(% of patients) Historical(2) AST-VAC1(1) VAC1 Phase 2 results, presented at ASCO, May 2015; manuscript submittedMayer NEJM 1994; Rollig, J Clin Onc 2011ITP is commonly observed in AML patients and may not
Slide 24: Optimizing Path Forward for AST-VAC1 Development
Optimizing Path Forward for AST-VAC1 Development Critical path item is development/enhancement of the AST-VAC1 production process; effort underway, projected completion mid-2017Key objectives: reduce cycle time, COGSPositive “end-of Phase 2” meeting with FDA; FDA would support proceeding directly to
Slide 25: AST-VAC2
Non-patient specific (allogeneic), “ready-for-use”Non-small cell lung cancer (NSCLC)Development partnership with Cancer Research UKPlanning Phase 1/2a clinical trial to start Q1 2017 AST-VAC2 14219863Text 04698Text 230237246Text
Slide 26: AST-VAC2 Targets an Unmet Need in NSCLC
AST-VAC2 Targets an Unmet Need in NSCLC, a Very Large Population of Cancer Patients with High Mortality Rate Not Staged3% Lung cancer is the most common type of cancer(1)Estimated 1.8M new cases and 1.6M lung cancer deaths worldwide in 2012~220,000 new cases and ~160,000 deaths annually in the U.S.8
Slide 27: AST-VAC2 is Allogeneic, 'Ready for Use,' Non-Patient Specific
AST-VAC2 is Allogeneic, ‘Ready for Use,’ Non-Patient Specific AST-VAC2 cells are mature allogeneic dendritic cells that have been transfected with hTERT and LAMP(4,5), similarly to AST-VAC1Not patient-specific: no need to produce individualized vaccines for each patientAST-VAC2 is ready to use on de
Slide 28: Phase 1/2a Trial to be Funded Through CRUK Partnership
Anticipate MHRA clearance for Phase 1/2a NSCLC trial by end 2016/early 2017Clinical trial enrollment projected to begin Q1 2017Partnership with Cancer Research UK (CRUK) funds full cost of GMP manufacturing, regulatory filing, and Phase 1/2a trialCRUK partnership saves Asterias an estimated ~$30MFol
Slide 29: Key Highlights
Key Highlights AST-OPC1Ongoing Phase 1/2a trial in spinal cord injury (SCI)Positive safety profile to-date in two safety cohorts (thoracic SCI trial and cervical SCI trial) Early signs of possible efficacy - one motor level improvement in all three patients in very low dose 2m cell safety cohortFirs
Slide 30: Appendix
APPENDIX 14219863Text 04698Text 230237246Text
Slide 31: Corporate History
Asterias: a publicly traded, independently operated company that is presently <48% owned by Biotime (BTX) September 2012 – BioTime (BTX) creates Asterias to acquire assets in the field of regenerative medicineOctober 2013 – Asterias acquires cell therapy assets from Geron, including INDs for the cli
Slide 32: AST-OPC1 Accomplishes Three Major Physiologically Relevant Functional Activities
AST-OPC1 Accomplishes Three Major Physiologically Relevant Functional Activities 14219863Text 04698Text 230237246Text shiverer mouse shi mouse + AST-OPC1 Wraps host neurons and forms compact myelin sheaths AST-OPC1 CM Control Media TubIII Produces neurotrophic factors and stimulates neurite outgrow
Slide 33: AST-OPC1: Demonstrated Activity in Preclinical SCI Model
AST-OPC1: Demonstrated Activity in Preclinical SCI Model hNucEC 1 mm 100 µm AST-OPC1 in SCI lesion, significantly reduced cavity formation Robust AST-OPC1 survival (brown) Myelinated fibers (blue) 9 Months Vehicle hNucEC 1 mm 100 µm Cavity forms in untreated SCI lesion Myelinated axons do not extend
Slide 34: AST-OPC1: Spinal Cord Anatomy and Levels of Injury
AST-OPC1: Spinal Cord Anatomy and Levels of Injury 14219863Text 04698Text 230237246Text Spinal cord injuries typically result in complete or partial loss of movement and sensation below the level of the injuryPatients with cervical injuries typically lose function in all four limbs (quadraplegia/tet
Slide 35: AST-VAC1: Significant Unmet Need to Extend Remission in AML
Rollig J Clin Onc 2011 Decision Resources Relapse-Free Survival (RFS) in AML Patients >60 years of Age Treated with Standard of Care(1) Only 10-20% RFS at 4 years AST-VAC1: Significant Unmet Need to Extend Remission in AML “The incidence of AML continues to increase with the aging population. The su
Slide 36: AST-VAC1: Safety Demonstrated in Phase 1 and Phase 2 Trials
AST-VAC1: Safety Demonstrated in Phase 1 and Phase 2 Trials AST-VAC1 demonstrated favorable safety profile in two clinical trialsOnly 1 out of 41 patients exhibited a possibly related SAE Patients Receiving VAC1 Safety Results Phase 1 TrialSu Z, Journal of Immunology 2005 20 patients with metastatic
Asterias Biotherapeutics — Investor Presentation (August 2016) on 6ix